Skip to content
healthcare.dev

Rybrevant Faspro

NDC 57894-522, AMIVANTAMAB and HYALURONIDASE-lpuj (HUMAN RECOMBINANT), injection, from Janssen Biotech, Inc..

Product NDC
57894-522
Status
Listed
Labeler
Janssen Biotech, Inc.
Dosage form
INJECTION
Route
SUBCUTANEOUS
Product type
HUMAN PRESCRIPTION DRUG
Marketing category
BLA
Application
BLA761433
DEA schedule
None
Request
curl https://api.healthcare.dev/v1/drugs/ndc/57894-522 \
  -H "Authorization: Bearer $HDEV_API_KEY"

Product

Active ingredients and packages

Active ingredients

  • AMIVANTAMAB3520 mg/22mL
  • HYALURONIDASE (HUMAN RECOMBINANT)44000 mg/22mL

Pharmacologic classes

Endoglycosidase [EPC]; Glycoside Hydrolases [CS]

Package NDCNDC-11Package
57894-522-01578940522011 VIAL, SINGLE-DOSE in 1 CARTON (57894-522-01) / 22 mL in 1 VIAL, SINGLE-DOSE

Linked data

RxNorm, label and prices

RxNorm concepts

Related lookups

  • FDA label sections

    GET /v1/drugs/labels/9e58b045-e352-4f62-99bf-77fae1bebc69
  • Medicare Part B payment limits (ASP)

    GET /v1/drugs/asp?ndc=57894-522

Use it

Look up 57894-522 from code or an agent

curl
curl https://api.healthcare.dev/v1/drugs/ndc/57894-522 \
  -H "Authorization: Bearer $HDEV_API_KEY"
MCP prompt
Using the healthcare.dev MCP server, look up NDC 57894-522. Tell me the product, its labeler, dosage form and route, its packages, and the RxNorm concepts it maps to.

Source: FDA, release 2026-10-23. Public domain. Reference data, not medical advice.